- Home
- NRSN vs INKT Comparison
NRSN vs INKT Comparison
Compare NRSN & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRSN
- INKT
- Stock Information
- Founded
- NRSN 2017
- INKT 2017
- Country
- NRSN Israel
- INKT United States
- Employees
- NRSN N/A
- INKT N/A
- Industry
- NRSN Biotechnology: Pharmaceutical Preparations
- INKT Medicinal Chemicals and Botanical Products
- Sector
- NRSN Health Care
- INKT Health Care
- Exchange
- NRSN Nasdaq
- INKT Nasdaq
- Market Cap
- NRSN 37.9M
- INKT 31.2M
- IPO Year
- NRSN 2021
- INKT 2021
- Fundamental
- Price
- NRSN $1.79
- INKT $7.26
- Analyst Decision
- NRSN Buy
- INKT Strong Buy
- Analyst Count
- NRSN 2
- INKT 2
- Target Price
- NRSN $14.00
- INKT $37.50
- AVG Volume (30 Days)
- NRSN 297.9K
- INKT 5.4K
- Earning Date
- NRSN 06-23-2025
- INKT 05-15-2025
- Dividend Yield
- NRSN N/A
- INKT N/A
- EPS Growth
- NRSN N/A
- INKT N/A
- EPS
- NRSN N/A
- INKT N/A
- Revenue
- NRSN N/A
- INKT N/A
- Revenue This Year
- NRSN N/A
- INKT N/A
- Revenue Next Year
- NRSN N/A
- INKT N/A
- P/E Ratio
- NRSN N/A
- INKT N/A
- Revenue Growth
- NRSN N/A
- INKT N/A
- 52 Week Low
- NRSN $0.51
- INKT $4.56
- 52 Week High
- NRSN $1.80
- INKT $13.79
- Technical
- Relative Strength Index (RSI)
- NRSN 73.77
- INKT 48.58
- Support Level
- NRSN $1.65
- INKT $6.98
- Resistance Level
- NRSN $1.77
- INKT $7.36
- Average True Range (ATR)
- NRSN 0.14
- INKT 0.31
- MACD
- NRSN 0.02
- INKT 0.03
- Stochastic Oscillator
- NRSN 100.00
- INKT 43.65
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.